Disease · MONDO_0001751
cholestasis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. cholestasis. Diseases, record MONDO_0001751. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001751
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 2 of its 9 drugs, from ClinicalTrials.gov, EMA Human Drugs and FDA
- Open Targets
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FISH OIL TRIGLYCERIDES | CHEMBL4297535 | Approval | ClinicalTrials.gov and FDA | 6 | 5 | 5 | Drugs and targets | |
| TOCOFERSOLAN | CHEMBL2108106 | Small molecule | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| MEDIUM-CHAIN TRIGLYCERIDES | CHEMBL4298042 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| OLIVE OIL | CHEMBL2107910 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| SOYBEAN OIL | CHEMBL1201485 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| FISH OIL | CHEMBL3833369 | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets | |
| URSODIOL | CHEMBL1551 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ODEVIXIBAT | CHEMBL4297588 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TAURURSODIOL | CHEMBL272427 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR1H4 | Bile acid receptor | 1 | Bile acid receptor FXR agonist | Phase 2 | https://conductscience.org/library/genes/9971 | Drugs and targets |
| SLC10A2 | Ileal sodium/bile acid cotransporter | 1 | Ileal bile acid transporter inhibitor | Phase 2 | https://conductscience.org/library/genes/6555 | Drugs and targets |
Trials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00738101 | Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants | Not applicable | 293 | 2020-05-21 | Cholestasis, Cholestasis of Parenteral Nutrition | FISH OIL TRIGLYCERIDES | Its record names the disease | ClinicalTrials.gov |
| NCT02579265 | Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants | Phase 3 | 204 | 2022-01-05 | Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days | MEDIUM-CHAIN TRIGLYCERIDES, OLIVE OIL, SOYBEAN OIL | Its record names the disease | ClinicalTrials.gov |
| NCT00826020 | Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis | Phase 2 | 72 | 2019-10-28 | Parenteral Nutrition Associated Liver Disease PNALD, Cholestasis | FISH OIL | Its record names the disease | ClinicalTrials.gov |
| NCT01601652 | Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis | Phase 1/2 | 12 | 2021-01-27 | Parenteral Nutrition Associated Cholestasis | FISH OIL TRIGLYCERIDES | Its record names the disease | ClinicalTrials.gov |
| NCT01845116 | Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury | Phase 2 | 11 | 2022-11-23 | Total Parenteral Nutrition-induced Cholestasis | FISH OIL, FISH OIL TRIGLYCERIDES | Its record names the disease | ClinicalTrials.gov |
| NCT01173159 | Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis | Not applicable | 10 | 2020-05-08 | Cholestasis | FISH OIL TRIGLYCERIDES | Its record names the disease | ClinicalTrials.gov |
| NCT03586674 | Fibrates in Pediatric Cholestasis | Phase 2 | 50 | Chronic Cholestasis | URSODIOL | Its record names the disease | ClinicalTrials.gov | |
| NCT02630875 | A4250, an IBAT Inhibitor in Pediatric Cholestasis | Phase 2 | 24 | Pediatric Cholestasis | ODEVIXIBAT | Its record names the disease | ClinicalTrials.gov | |
| NCT02420496 | Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants | Phase 2 | 0 | Cholestasis, Liver Disease | FISH OIL, URSODIOL | Its record names the disease | ClinicalTrials.gov | |
| NCT01412359 | Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury | Total Parenteral Nutrition-induced Cholestasis | FISH OIL TRIGLYCERIDES | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Intralipid® 20% vs Smoflipid 20%: Number of Patients With 1 or More Bloodstream Infections to Number of Patients on Study Medication | 5 of 78 | 6 of 83 | 161 | NCT02579265 | Trial comparisons |
| Intralipid® 20% vs Smoflipid 20%: deaths from any cause | 1 of 78 | 1 of 83 | 161 | NCT02579265 | Trial comparisons |
| Intralipid® 20% vs Smoflipid 20%: Number of Patients Who Complete PN Treatment Without Lipid Minimization | 73 of 78 | 79 of 83 | 161 | NCT02579265 | Trial comparisons |
| Intralipid® 20% vs Smoflipid 20%: serious adverse events | 5 of 78 | 8 of 83 | 161 | NCT02579265 | Trial comparisons |
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001751
GET https://conductscience.org/api/diseases/v1/MONDO_0001751/drugs